SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

Ele Ferrannini(University of Pisa), Anna Solini(University of Pisa)

Nature Reviews Endocrinology

February 7, 2012

10.1038/nrendo.2011.243

Cited by 459

Abstract

Related Papers

Phlorizin: a review

Joel Ehrenkranz, Norman Lewis, C. Ronald Kahn et al.|Diabetes/Metabolism Research and Reviews|2004|921

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

Michael A. Nauck, Stefano Del Prato, Juris J. Meier et al.|Diabetes Care|2011|529

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Bernard J. Komoroski, N. Vachharajani, Y Feng et al.|Clinical Pharmacology & Therapeutics|2009|388

Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

Sue Sha, Damayanthi Devineni, A. Ghosh et al.|Diabetes Obesity and Metabolism|2011|294

Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic Subjects

Carl Erik Mogensen|Scandinavian Journal of Clinical and Laboratory Investigation|1971|219